Le Lézard
Classified in: Health
Subject: LBR

/R E P E A T -- MEDIA ADVISORY - ONA President, 1st Vice-President Join Registered Nurses at Rally to Stop Cuts at Health Sciences North/


SUDBURY, ON, Sept. 13, 2018 /CNW/ - Registered Nurses (RNs) and Ontario Nurses' Association (ONA) President Vicki McKenna, RN, will join with CUPE members at a rally to stop RN and staffing cuts at Health Sciences North tomorrow.

The hospital has announced 60.5 full-time-equivalent RN cuts, as well as cuts to other positions. The RNs will also be joined by ONA First Vice-President, Cathryn Hoy, RN, at the rally.

ONA notes that Health Sciences North is already operating overcapacity. The RN cuts will worsen a situation where hallway care is already becoming the norm, with patients on gurneys in offices and hallways, which is inappropriate for the proper care and recovery of patients.

ONA is the union representing more than 65,000 registered nurses and health-care professionals, as well as 18,000 nursing student affiliates, providing care in hospitals, long-term care facilities, public health, the community, clinics and industry.

WHAT:

Rally to stop the cuts at Health Sciences North

WHO:

ONA President, First Vice-President, front-line RNs

WHEN: 

Friday, September 14, 2018. ONA President to speak at noon.

WHERE:

Main sidewalk, Paris Street, Sudbury (in front of the Children's Treatment Centre)

 

Visit us at: www.ona.org; Facebook.com/OntarioNurses; www.Twitter.com/OntarioNurses

SOURCE Ontario Nurses Association


These press releases may also interest you

at 04:00
Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024,...

at 04:00
TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and...

at 03:26
Calliditas Therapeutics AB , ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine...

at 03:00
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...

at 03:00
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...



News published on and distributed by: